Patient characteristics and treatment outcomes
. | . | . | . | . | . | Response to imatinib* . | . | . | GVHD (grade) . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Age, y/sex . | BCR-ABL isoform . | Karyotype . | Status before imatinib . | Imatinib dose . | After first imatinib . | After second imatinib . | Pre-SCT status . | Acute . | Chronic . | Current LFS status; cause of death . | ||
| 1 | 39/F | p190 (e1a2) | Additional | CHR | 600 mg/d | CHR (-0.20) | Mol CR (UD) | Mol CR | + (II) | + (E) | Alive 28 + mo | ||
| 2 | 29/M | p210 (b3a2) | Additional | CHR | 400 mg/d | CHR (-0.89) | CHR (-0.27) | CHR | - | - | Alive 27 + mo | ||
| 3 | 40/M | p210 (b2a2) | Additional | CHR | 600 mg/d | CHR (-0.40) | CHR (-0.79) | CHR | - | + (L) | Alive 25 + mo | ||
| 4 | 39/F | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-0.35) | Mol CR (UD) | Mol CR | - | - | Alive 24 + mo | ||
| 5 | 26/M | p190 (e1a2) | Ph alone | CHR | 400 mg/d | CHR (-1.22) | CHR (-0.31) | CHR | - | - | Alive 21 + mo | ||
| 6 | 20/M | p210 (b2a2) | Additional | CHR | 600 mg/d | CHR (-0.97) | CHR (-0.08) | CHR | - | + (L) | Alive 19 + mo | ||
| 7 | 43/F | p210 (b3a2) | Additional | CHR | 600 mg/d | CHR (-1.85) | CHR (-0.09) | CHR | + (III) | NA | Died 3 mo; TRM | ||
| 8 | 40/F | p190 (e1a2) | Ph alone | CHR | 600 mg/d | CHR (-0.50) | CHR (-1.09) | CHR | - | - | Alive 16 + mo | ||
| 9 | 31/M | p210 (b3a2) | Ph alone | CHR | 400 mg/d | CHR (-0.93) | CHR (-0.11) | CHR | - | - | Alive 14 + mo | ||
| 10 | 27/M | p190 (e1a2) | Additional | CHR | 600 mg/d | Relapse (+0.93) | Relapse (+1.63) | Relapse | NA | NA | Died before SCT; sepsis | ||
| 11 | 38/F | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-0.20) | CHR (-0.07) | CHR | + (II) | + (E) | Alive 11 + mo | ||
| 12 | 39/M | p210 (b3a2) | Ph alone | Refractory | 600 mg/d | CHR (-0.89) | NA | CHR | - | + (L) | Alive 10 + mo | ||
| 13 | 30/M | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-1.48) | NA | CHR | - | - | Alive 9 + mo | ||
| 14 | 44/M | p190 (e1a2) | Additional | Refractory | 600 mg/d | Refractory (+0.54) | NA | Refractory | + (IV) | NA | Died 4 mo; TRM | ||
. | . | . | . | . | . | Response to imatinib* . | . | . | GVHD (grade) . | . | . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. . | Age, y/sex . | BCR-ABL isoform . | Karyotype . | Status before imatinib . | Imatinib dose . | After first imatinib . | After second imatinib . | Pre-SCT status . | Acute . | Chronic . | Current LFS status; cause of death . | ||
| 1 | 39/F | p190 (e1a2) | Additional | CHR | 600 mg/d | CHR (-0.20) | Mol CR (UD) | Mol CR | + (II) | + (E) | Alive 28 + mo | ||
| 2 | 29/M | p210 (b3a2) | Additional | CHR | 400 mg/d | CHR (-0.89) | CHR (-0.27) | CHR | - | - | Alive 27 + mo | ||
| 3 | 40/M | p210 (b2a2) | Additional | CHR | 600 mg/d | CHR (-0.40) | CHR (-0.79) | CHR | - | + (L) | Alive 25 + mo | ||
| 4 | 39/F | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-0.35) | Mol CR (UD) | Mol CR | - | - | Alive 24 + mo | ||
| 5 | 26/M | p190 (e1a2) | Ph alone | CHR | 400 mg/d | CHR (-1.22) | CHR (-0.31) | CHR | - | - | Alive 21 + mo | ||
| 6 | 20/M | p210 (b2a2) | Additional | CHR | 600 mg/d | CHR (-0.97) | CHR (-0.08) | CHR | - | + (L) | Alive 19 + mo | ||
| 7 | 43/F | p210 (b3a2) | Additional | CHR | 600 mg/d | CHR (-1.85) | CHR (-0.09) | CHR | + (III) | NA | Died 3 mo; TRM | ||
| 8 | 40/F | p190 (e1a2) | Ph alone | CHR | 600 mg/d | CHR (-0.50) | CHR (-1.09) | CHR | - | - | Alive 16 + mo | ||
| 9 | 31/M | p210 (b3a2) | Ph alone | CHR | 400 mg/d | CHR (-0.93) | CHR (-0.11) | CHR | - | - | Alive 14 + mo | ||
| 10 | 27/M | p190 (e1a2) | Additional | CHR | 600 mg/d | Relapse (+0.93) | Relapse (+1.63) | Relapse | NA | NA | Died before SCT; sepsis | ||
| 11 | 38/F | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-0.20) | CHR (-0.07) | CHR | + (II) | + (E) | Alive 11 + mo | ||
| 12 | 39/M | p210 (b3a2) | Ph alone | Refractory | 600 mg/d | CHR (-0.89) | NA | CHR | - | + (L) | Alive 10 + mo | ||
| 13 | 30/M | p190 (e1a2) | Additional | CHR | 400 mg/d | CHR (-1.48) | NA | CHR | - | - | Alive 9 + mo | ||
| 14 | 44/M | p190 (e1a2) | Additional | Refractory | 600 mg/d | Refractory (+0.54) | NA | Refractory | + (IV) | NA | Died 4 mo; TRM | ||
LFS indicates leukemia-free survival; F, female; M, male; Mol CR, molecular complete remission; UD, undetectable; +, presence of GVHD; —, absence of GVHD; E, extensive; L, limited; NA, not available; and TRM, transplant-related mortality.
Values in parentheses indicate the changes of BCR-ABL/ABL ratio between each paired sample (before and after imatinib level).